4-Week TB pill could revolutionize prevention for millions at risk
NCT ID NCT06568484
First seen Jan 05, 2026 · Last updated Apr 30, 2026 · Updated 13 times
Summary
This study tests whether a 4-week course of the drug bedaquiline can prevent tuberculosis (TB) as well as the standard longer treatments. It involves 2,530 people living with HIV and close contacts of TB patients. The goal is to find a safer, shorter, and easier prevention option for those at high risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, LATENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
HNSEB (Hospital Nacional Sergio E. Bernales)
Lima, Peru
Contact Email: •••••@•••••
-
Joint Clinical Research Centre
Kampala, Uganda
Contact Email: •••••@•••••
-
Kilimanjaro Clinical Research Institute
Moshi, Tanzania
Contact Email: •••••@•••••
-
MU-JHU Care Ltd.
Kampala, Uganda
Contact Email: •••••@•••••
-
Makerere Lung Institute
Kampala, Uganda
Contact Email: •••••@•••••
-
SES Policlinico
Lima, Peru
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.